Kevan M. Shokat
Molecular Biology · 2000–2021
A researcher in the Science corpus: 23 papers; trusts 3 researchers and is trusted by 8 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 263 citations into it; #5,533 of 17,773 by trust here, #1,049 by citations
- Spectroscopy — 27 citations into it
- Computational Theory and Mathematics — 18 citations into it
- Pharmacology — 11 citations into it
Whom Kevan M. Shokat trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Kevan M. Shokat overall
Papers from Kevan M. Shokat's perspective
Ordered by how strongly the researchers Kevan M. Shokat trusts endorse each paper. Same corpus, a different order for every researcher.
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers (Science)
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex (Science)
- mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. (Cell)
- The specificities of protein kinase inhibitors: an update. (Biochemical Journal)
- Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity (Nature)
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancer (Nature Reviews. Cancer)
- Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. (Proceedings of the National Academy of Sciences of the United States of America)
- Specificity and mechanism of action of some commonly used protein kinase inhibitors
- mTOR and cancer: insights into a complex relationship (Nature Reviews. Cancer)
Their papers
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. (2006) — 617 citations
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 (2009) — 1,174 citations
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling (2006) — 1,146 citations
- A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing (2020) — 3,895 citations
- RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF (2010) — 1,791 citations
- The translational landscape of mTOR signalling steers cancer initiation and metastasis (2012) — 1,314 citations
- Targets of the cyclin-dependent kinase Cdk1 (2003) — 984 citations
- Features of selective kinase inhibitors. (2005) — 647 citations
- IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response (2007) — 1,392 citations
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions (2013) — 2,245 citations
- A chemical switch for inhibitor-sensitive alleles of any protein kinase (2000) — 1,081 citations
- The LuxS family of bacterial autoinducers: biosynthesis of a novel quorum‐sensing signal molecule (2001) — 1,049 citations
- The unfolded protein response signals through high-order assembly of Ire1 (2008) — 639 citations
- Targeting the cancer kinome through polypharmacology (2010) — 673 citations
- Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant (2021) — 97 citations
- Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. (2020) — 659 citations
- The Global Phosphorylation Landscape of SARS-CoV-2 Infection (2020) — 946 citations
- Drugging the ‘undruggable’ cancer targets (2017) — 753 citations
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR (2008) — 893 citations
- Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 (2007) — 1,006 citations